DOCSLIB.ORG

RESTRICTED Bayer Annual Report 2020 Five-Year Summary 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Bayer-Geschäftsbericht 2018 A Zusammengefasster Lagebericht 1 Fehler! Kein Text mit angegebener Formatvorlage im Dokument. Annual Report RESTRICTED Bayer Annual Report 2020 Five-Year Summary 2 Five-Year Summary € million 2016 2017 2018 2019 2020 Bayer Group financial KPIs Sales 34,943 35,015 36,742 43,545 41,400 EBITDA1 8,801 8,563 9,695 9,529 (2,910) EBITDA before special items1 9,318 9,288 8,969 11,474 11,461 EBITDA margin before special items1 26.7% 26.5% 24.4% 26.3% 27.7% EBIT1 5,738 5,903 3,454 4,162 (16,169) EBIT before special items1 6,826 7,130 6,013 6,975 7,095 Income before income taxes 4,773 4,577 1,886 2,853 (17,250) Net income (from continuing and discontinued operations) 4,531 7,336 1,695 4,091 (10,495) Earnings per share (from continuing and discontinued operations) (€)1 5.44 8.29 1.80 4.17 (10.68) Core earnings per share (from continuing operations) (€)1 6.67 6.64 5.60 6.38 6.39 Free cash flow 5,806 5,202 4,652 4,214 1,343 Net financial debt 11,778 3,595 35,679 34,068 30,041 Capital expenditures (newly capitalized) 2,627 2,418 2,368 2,920 3,138 Return on Capital Employed (ROCE) (%) 10.3 10.8 4.0 3.7 – 16,5 Bayer AG Total dividend payment 2,233 2,402 2,611 2,751 1,965 Dividend per share (€) 2.70 2.80 2.80 2.80 2.00 Bayer Group nonfinancial KPIs2 Number of smallholder farmers in LMICs who have received support (million) – – – 42 45 Number of women in LMICs who have gained access to modern contraception (million) – – – 38 40 Number of people in underserved communities whose self-care needs have been supported by Bayer interventions (million) – – – 41 43 Scope 1 & 2 greenhouse gas emissions (million t) – – – 3.76 3.58 Scope 3 greenhouse gas emissions from relevant categories (million t) – – – 8.87 7.88 Off-setting of remaining Scope 1 & 2 greenhouse gas emissions (million t) – – – 0.0 0.20 Innovation Research and development expenses3 4,405 4,504 5,105 5,301 7,126 Ratio of R&D expenses to sales – Crop Science (%)4 11.7 11.7 13.0 11.3 10.4 Ratio of R&D expenses to sales – Pharmaceuticals (%)4 16.7 16.2 15.5 15.6 15.5 Ratio of R&D expenses to sales – Consumer Health (%)4 3.9 3.9 4.1 3.9 3.8 Employees Number of employees5 (Dec. 31) 99,592 99,820 107,894 103,824 99,538 Personnel expenses (including pension expenses) (€ million) 9,459 9,528 10,778 11,788 9,769 Safety & Environmental Protection Recordable Incident Rate (RIR) for Bayer employees 0.40 0.45 0.40 0.46 0.32 Process Safety Incident Rate (PSI-R) – – – 0.10 0.08 Total energy consumption (terajoules) 26,243 25,832 28,903 39,212 35,858 6 Energy efficiency (kWh / €1,000) 209 205 219 250 241 Hazardous waste generated (thousand t) 428 485 303 316 305 Water use (million m³) 93 98 42 59 57 2019 figures restated; figures for 2016 – 2018 as last reported 1 For definitions of the indicators see A 2.3. 2 For more information see A 1.2.1 3 The increase in research and development expenses in 2020 was mainly due to special charges in connection with the impairment charges at Crop Science. 4 R&D expenses before special items 5 Employees calculated as full-time equivalents (FTEs) 6 Quotient of total energy consumption and external sales Bayer Annual Report 2020 At a Glance 3 Fiscal 2020: Bayer delivers robust performance despite pandemic – foundation laid for future growth // Group sales at €41.4 billion, impacted by negative currency effects of €1.9 billion (Fx & p adj. + 0.6%) // EBITDA before special items unchanged at €11.5 billion – currency effects offset by stringent cost management // Crop Science and Pharmaceuticals report stable operational business, Consumer Health sees strong growth // Core earnings per share at €6.39 (+ 0.2%) // Earnings per share at – €10.68, impacted by litigation provisions and impairments // Net financial debt improves to €30.0 billion // Proposed dividend of €2.00 per share // Portfolio and innovation capabilities strengthened // Outlook for 2021: positive momentum and solid operational growth – stable earnings at constant currencies Bayer Annual Report 2020 Contents 4 Contents To our Stockholders Chairman’s Letter __________________________________________ 6 Board of Management __________________________________ 12 Report of the Supervisory Board _____________________ 13 Investor Information _____________________________________ 21 About this Report _________________________________________ 25 A Combined Management Report 1. Fundamental Information About the Group _____ 27 3.1.2 Corporate Outlook ____________________________________ 100 1.1 Corporate Profile and Structure ________________________ 27 3.2 Opportunity and Risk Report _________________________ 101 1.1.1 Corporate Profile _______________________________________ 27 3.2.1 Group-wide Opportunity and 1.1.2 Corporate Structure ____________________________________ 27 Risk Management System ____________________________ 101 1.2 Strategy and Management _____________________________ 32 3.2.2 Opportunity and Risk Status __________________________ 105 1.2.1 Strategy and Targets ___________________________________ 32 3.2.3 Overall Assessment of Opportunities and Risks 1.2.2 Sustainability Management ____________________________ 37 by the Board of Management _________________________ 114 1.2.3 Management Systems __________________________________ 39 1.3 Focus on Innovation __________________________________ 40 4. Corporate Governance Report ___________________ 115 1.4 Commitment to Employees ____________________________ 57 4.1 Declaration by Corporate Management 1.5 Procurement and Supplier Management_______________ 62 Pursuant to Sections 289f and 315d of the 1.6 Product Stewardship ___________________________________ 64 German Commercial Code ____________________________ 115 1.7 Environmental Protection and Safety __________________ 67 4.2 Compliance ___________________________________________ 119 4.3 Disclosures Pursuant to Sections 289b 2. Report on Economic Position ______________________ 71 Through e and 315b and c of the German 2.1 Overview of Business Performance ____________________ 71 Commercial Code _____________________________________ 121 2.1.1 Economic Position and Target Attainment ____________ 71 4.4 Compensation Report ________________________________ 121 2.1.2 Key Events ______________________________________________ 72 4.4.1 Compensation of the Board of Management _________ 122 2.1.3 Economic Environment _________________________________ 76 4.4.2 Compensation and Benefits Granted and Their 2.2 Earnings; Asset and Financial Position Allocation to Members of the Board of Management 140 of the Bayer Group _____________________________________ 77 4.4.3 Development of Board of Management 2.2.1 Earnings Performance of the Bayer Group ____________ 77 Compensation Relative to Employee Compensation 2.2.2 Business Development by Division ____________________ 82 and the Financial Performance of the Company _____ 143 2.2.3 Value-Based Performance _____________________________ 90 4.4.4 Compensation of the Supervisory Board _____________ 145 2.2.4 Asset and Financial Position of the Bayer Group ______ 91 4.4.5 Further Information ___________________________________ 147 2.3 Alternative Performance Measures Used 4.5 Takeover-Relevant Information _______________________ 147 by the Bayer Group _____________________________________ 96 5. Information on Bayer AG ___________________________ 149 3. Report on Future Perspectives and 5.1 Earnings Performance of Bayer AG __________________ 149 on Opportunities and Risks _________________________ 99 5.2 Asset and Financial Position of Bayer AG ____________ 152 3.1 Future Perspectives ____________________________________ 99 5.3 Forecast, Opportunities and Risks for Bayer AG _____ 154 3.1.1 Economic Outlook ______________________________________ 99 5.4 Nonfinancial and Other Disclosures by Bayer AG ____ 155 Bayer Annual Report 2020 Contents 5 B Consolidated Financial Statements Bayer Group Consolidated Income Statements _____________ 156 21. Equity __________________________________________________ 207 Bayer Group Consolidated Statements 22. Provisions for pensions and of Comprehensive Income ___________________________________ 157 other post-employment benefits ______________________ 209 Bayer Group Consolidated Statements 23. Other provisions _______________________________________ 218 of Financial Position _________________________________________ 158 24. Financial liabilities ____________________________________ 221 Bayer Group Consolidated Statements 25. Trade accounts payable ______________________________ 223 of Changes in Equity _________________________________________ 159 26. Other liabilities ________________________________________ 223 Bayer Group Consolidated Statements of Cash Flows _____ 160 27. Financial instruments _________________________________ 224 27.1 Financial instruments by category ____________________ 224 Notes to the Consolidated Financial Statements 27.2 Maturity analysis ______________________________________ 230 of the Bayer Group ___________________________________________ 161 27.3 Information on derivatives ____________________________ 231 1. General information ___________________________________ 161 28. Leases _________________________________________________ 234 2. Effects of new financial reporting standards _________ 161 29. Contingent liabilities and 3. Reporting policies, methods and other financial commitments __________________________ 236 critical accounting estimates _________________________ 164 30. Legal risks _____________________________________________ 237 4. Segment reporting ____________________________________
Recommended publications
  • Conversion Report (PDF, 958

    Conversion Report (PDF, 958

    This document is an English translation of the original German language document. The translation is exclusively for convenience purposes. Only the original German language document is authorative and binding. Fresenius SE Change of the Legal Form into a Partnership Limited by Shares Conversion Report of the Management Board Convenience Translation Important Notice: This conversion report is neither an offer to sell voting ordinary bearer shares or non-voting preference bearer shares, nor an invitation to make the Company an offer to buy voting ordinary bearer shares or non-voting preference bearer shares. Such an offer requires special publication as the case may be, and, in so far as required by national law, a separate prospectus. This conversion report is not an offer to sell securities in the United States of America (USA). Securities may be sold or offered for purchase in the USA only with prior registration or without prior registration only on the basis of an exception provided. This conversion report is neither an offer to sell voting ordinary limited partner shares nor an invitation to make the Company an offer to buy voting ordinary limited partner shares. Such an offer requires special publication as the case may be, and, in so far as required by national law, a separate prospectus. This conversion report is not an offer to sell securities in the USA. Securities may be sold or offered for purchase in the USA only with prior registration or without prior registration only on the basis of an exception provided. This document does not constitute an offer document or an offer of transferable securities to the public in the United Kingdom to which section 85 of the Financial Services and Markets Act 2000 of the United Kingdom (“FSMA”) applies and should not be considered as a recommen- dation that any person should subscribe for or purchase any securities as part of the Transaction.
  • Assortment Planning

    Assortment Planning

    3DEXPERIENCE for CPG & RETAIL September 2013 1 Our Legacy 2 Our new strategy ‘Social Industry Experiences’ Why Experiences? Consumers buy Experiences An Experience is Bigger Than a Product 3 CPG & RETAIL Segments 4 TOP 5 Cosmetics: Top Markets & Leaders Top 10 Countries of A balanced global market representative of most CPG segments Leaders (HQ) RUSSIA UK France Germany UNITED STATES Spain Italy CHINA JAPAN BRASIL Leaders : L’Oréal, P&G, Unilever, Estée Lauder, Shiseido, Avon, Kao, Beiersdorf, Johnson & Johnson, Chanel 5 Consumer Packaged Goods - Challenges 6 Consumer Packaged Goods : Innovation (Forbes 2013 ranking) 1 Salesforce.com 26 Fanuc 51 Smith & Nephew 76 Roper Industries 2 Alexion Pharmaceuticals 27 Diageo 52 Mondelēz International 77 ASML Holding 3 VMware 28 Hershey 53 Infosys 78 Assa Abloy 4 Regeneron Pharmaceuticals 29 Danone 54 Kellogg 79 Apple 5 ARM Holdings 30 Procter & Gamble 55 Ultrapar Participacoes 80 Air Products & Chemicals 6 Baidu 31 Dassault Systemes 56 Intuit 81 Tenaris 7 Amazon.com 32 Colgate-Palmolive 57 Technip 82 Precision Castparts 8 Intuitive Surgical 33 Ecolab 58 PepsiCo 83 Rockwell Automation 9 Rakuten 34 Monsanto 59 Schlumberger 84 Nintendo 10 Natura Cosmeticos 35 Reckitt Benckiser Group 60 Fresenius Medical Care 85 Cameron International 11 Henan Shuanghui 36 Keyence 61 SMC Corp 86 Secom 12 Coloplast 37 Kone 62 Valeant Pharmaceuticals Intl 87 Schindler Holding 13 Cerner 38 Yahoo Japan 63 Unilever NV 88 Campbell Soup 14 Unicharm 39 BRF-Brasil Foods 64 China Oilfield Services 89 Kubota 15 Estee Lauder Cos
  • Controlling Pregnancy: Fred Lyman Adair and the Influence of Eugenics on the Development of Prenatal Care

    Controlling Pregnancy: Fred Lyman Adair and the Influence of Eugenics on the Development of Prenatal Care

    Yale University EliScholar – A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2019 Controlling Pregnancy: Fred Lyman Adair And The nflueI nce Of Eugenics On The evelopmeD nt Of Prenatal Care Florence Hsiao Follow this and additional works at: https://elischolar.library.yale.edu/ymtdl Recommended Citation Hsiao, Florence, "Controlling Pregnancy: Fred Lyman Adair And The nflueI nce Of Eugenics On The eD velopment Of Prenatal Care" (2019). Yale Medicine Thesis Digital Library. 3504. https://elischolar.library.yale.edu/ymtdl/3504 This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital Platform for Scholarly Publishing at Yale. For more information, please contact [email protected]. Controlling Pregnancy: Fred Lyman Adair and the Influence of Eugenics on the Development of Prenatal Care A Thesis Submitted to the Yale University School of Medicine In Partial Fulfillment of the Requirements for the Degree of Doctor of Medicine By Florence Hsiao Class of 2019 Abstract This thesis examines the development of prenatal care in the United States in the early 1900s by focusing on the life and career of Fred Lyman Adair who, as an obstetrician and eugenicist, played a significant role in shaping prenatal care into what it is today. Although prenatal care was a product of infant welfare activists and public health officials, obstetricians like Adair who struggled to establish obstetrics as a legitimate specialty, saw an opportunity in prenatal care to pathologize pregnancy and elevate their specialty.
  • Managing Political Risk in Global Business: Beiersdorf 1914-1990

    Managing Political Risk in Global Business: Beiersdorf 1914-1990

    Managing Political Risk in Global Business: Beiersdorf 1914-1990 Geoffrey Jones Christina Lubinski Working Paper 12-003 July 22, 2011 Copyright © 2011 by Geoffrey Jones and Christina Lubinski Working papers are in draft form. This working paper is distributed for purposes of comment and discussion only. It may not be reproduced without permission of the copyright holder. Copies of working papers are available from the author. Managing Political Risk in Global Business: Beiersdorf 1914-1990 Geoffrey Jones Christina Lubinski 1 Abstract This working paper examines corporate strategies of political risk management during the twentieth century. It focuses especially on Beiersdorf, a German-based pharmaceutical and skin care company. During World War 1 the expropriation of its brands and trademarks revealed its vulnerability to political risk. Following the advent of the Nazi regime in 1933, the largely Jewish owned and managed company, faced a uniquely challenging combination of home and host country political risk. The paper reviews the firm's responses to these adverse circumstances, challenging the prevailing literature which interprets so-called "cloaking" activities as one element of businesses’ cooperation with the Nazis. The paper departs from previous literature in assessing the outcomes of the company’s strategies after 1945. It examines the challenges and costs faced by the company in recovering the ownership of its brands. While the management of distance became much easier over the course of the twentieth century because of communications
  • An Overview: Innovation in Plant Breeding

    An Overview: Innovation in Plant Breeding

    An Overview: Innovation in Plant Breeding Modern plant breeding blends traditional ways of developing crops with the latest in science and technology to achieve improved crops – enabling more choices for both farmers and consumers, and producing crops that can better cope with evolving pests, diseases and a changing climate. The Basics What: The simplest definition of plant breeding is crossing two plants Most of the fruits, vegetables, and to produce offspring that share the best characteristics of the two grains that we eat today are the parent plants. Breeders make crosses then select which offspring to advance in the pipeline based on their desired characteristics. result of generations of plant breeding. About 5,000 years ago, Why: Even the earliest farmers understood that, in order to survive, watermelons were only they needed plant varieties specifically adapted to their environmental conditions and cultivated to produce the best foods to nourish their 2 inches in diameter livestock and communities. and had a bitter taste, vastly How: Through generations of research and discovery, plant breeding has advanced beyond selecting a parent plant simply based on its different from appearance. It now includes an in-depth understanding of plants’ the large, genetic makeup, enabling breeders to better predict which plants will sweet-tasting have the highest probability of success in the field and the grocery fruit we enjoy store before making a cross. today. The Background The earliest farmers were plant breeders who understood the value of identifying crops that showed beneficial characteristics to plant in future seasons. Later, they learned they could cross two plants to develop an even better plant.
  • TRIPS and MONOPOLIES on SEEDS and MEDICINES Vandana

    TRIPS and MONOPOLIES on SEEDS and MEDICINES Vandana

    295 PROFITEERING FROM DEATH: TRIPS AND MONOPOLIES ON SEEDS AND MEDICINES Vandana Shiva 1 1 WTO AND THE TRIPS AGREEMENT The Trade Related Intellectual Property Rights Agreement of WTO is the most far reaching in terms of creating corporate rights and corporate monopolies. During the Uruguay Round of the GATT, the United States introduced its flawed patent system into the WTO, and thus imposed it on the rest of the world. US Corporations have admitted that they drafted and lobbied on behalf of TRIPs. As a Monsanto spokesman said, “The industries and traders of world commerce have played simultaneously the role of patients, the diagnosticians, and prescribing physicians.” TRIPs not only made Intellectual Property Rights (IPR) laws global geographically, but also removed ethical boundaries by including life forms and biodiversity into patentable subject matter. Living organisms and life forms that are self-creating were thus redefined as machines and artifacts made and invented by the patentee. Intellectual property rights and patents then give the patent holder a monopolistic right to prevent others from making, using, or selling seeds. Seed saving by farmers has now been redefined from a sacred duty to a criminal offence of stealing “property”. Article 27.3 (b) of the TRIPs agreement, which relates to patents on living resources, was basically pushed by the “Life Science” companies to establish themselves as Lords of Life. The chemical companies of the world have bought up seed and biotechnology companies and reorganized themselves as Life Science corporations, claiming patents on genes, seeds, plants and animals. Ciba Geigy and Sandoz have combined to form Novartis, Hoechst has joined with Rhone 1 Phd in the Philosophy of Science (1978) , Right Livelihood Award (1993), director of the Research Foundation for Science, Technology and Ecology, New Delhi, India.
  • The Debate on the Golden Rice and Its Background

    The Debate on the Golden Rice and Its Background

    The Debate on the Golden Rice and its Background A Literature Review Klaus Ammann, [email protected] Dedicated to the inventor and relentless promoter of Golden Rice, Ingo Potrykus Judge GM crops on their properties, not the technique used to make them – and we can start saving lives Editorial help: Vivian Moses, Patrick and Michael Moore 20140615 references numbered with full text links Millions of children die worldwide every year, an untenable situation that is still worsening which needs immediate correction. According to the World Health Organization (1), an estimated 250 million preschool children are vitamin A deficient (= VAD) and it is likely that in VAD areas a substantial proportion of pregnant women are also affected in 2013. Earlier reports (2) make evident that the problems are still growing: (in 2004: 140 million preschool children and more than 7 million pregnant women were suffering from VAD) 2 Preface It is not the intention of the author for this literature compilation on Golden Rice to replace the two websites www.goldenrice.org and www.allowgoldenricenow.org, they contain major information pieces, are well organized and specific information is easy to access. Rather it is the aim here to pull together a set of publications related to the background of the Golden Rice debate. We often are confronted with all kinds of determined opinions about the Golden Rice, Bio-Fortification, Transgenic Plants, Traditional and Organic Agriculture etc. and it is the purpose of this summary to shed light to the background of opinions pro and contra the Golden Rice – on how and why those opinions grow and how they are unfortunately melting down into simplistic slogans.
  • View Presentation

    View Presentation

    Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva1 Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva Amgen Daiichi Sankyo Bayer Boehringer Ingelheim Merck & Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda
  • Research Aktuell Vom 05.05.2020

    Research Aktuell Vom 05.05.2020

    5. Mai 2020 Marktdaten im Überblick ...................................................................................................................... 2 Unternehmenskommentare .................................................................................................................. 3 Airbus ............................................................................................................................................... 3 Altria Group ....................................................................................................................................... 5 Beiersdorf ......................................................................................................................................... 7 Microsoft ......................................................................................................................................... 13 MTU Aero Engines ............................................................................................................................ 15 Roche Holding (Genussschein) ......................................................................................................... 21 Safran ............................................................................................................................................. 23 Rechtliche Hinweise ........................................................................................................................... 25 DAILY Marktdaten im Überblick 04.05.2020 01.05.2020 Änderung Deutschland DAX
  • A Global Citizens Report on the State of Gmos Synthesis Report !"#$%&'$#&(#)')$ "*+$,'$-.'!"#+

    A Global Citizens Report on the State of Gmos Synthesis Report !"#$%&'$#&(#)')$ "*+$,'$-.'!"#+

    !"#$%&'$#&(#)')$ "*+$,'$-.'!"#+ Published by A Global Citizens Report on the State of GMOs Synthesis Report !"#$%&'$#&(#)')$ "*+$,'$-.'!"#+ !"#$%&'$"()*)+,-."/,0%1*" %-"*2,"3*'*,"%4"#56."7 8'$.,"91%:).,.;"8')$,<"=,>2-%$%?),. 3@-*2,.)."/,0%1* Coordinated by Vandana Shiva, Navdanya Debbie Barker, Centre for Food Safety Caroline Lockhart, Navdanya International Front page cartoon: Sergio Staino Layout, production and printing: SICREA srl, Florence Contact: [email protected] Available for download at www.navdanyainternational.it www.navdanya.org Thanks go to all those who readily contributed in the realization of this report, particularly Sergio Staino, creator of the cover cartoon, Maurizio Izzo of Sicrea for production and Massimo Orlandi for press and communications. Thanks also go to Christina Stafford and interns Tara McNerney and Tanvi Gadhia of Center for Food Safety (CFS) and Sulakshana Fontana, Elena Bellini and Filippo Cimo of Navdanya International for their diligent coordination, editing and translation efforts. Final thanks also go to Giannozzo Pucci, Maria Grazia Mammuccini and Natale Bazzanti for their cooperation and assistance in realizing this report. This publication is printed on ecological paper SYMBOL FREELIFE SATIN ECF *$%/012/$-3435678$)690:4$ 07$4;6$+4246$0<$%&'8$=$ >2/86$(:0?3868@$>23/6A$!6B;70/0C368 Coordinated by Navdanya and Navdanya International, the International Commission on the Future of Food and Agriculture, with the participation of The Center for Food Safety (CFS) Contributing organizations:
  • List of Active Bayer Companies with at Least a Share of 50% Last Update: 17.8.2020 Country Company

    List of Active Bayer Companies with at Least a Share of 50% Last Update: 17.8.2020 Country Company

    List of active Bayer companies with at least a share of 50% last update: 17.8.2020 Country Company Algeria Bayer Algerie S.P.A. Argentina Bayer S.A. Argentina Biagro S.A. Argentina Monsanto Argentina SRL Australia Bayer Australia Limited Australia Bayer CropScience Holdings Pty Ltd Australia Bayer CropScience Pty Limited Australia Cotton Growers Services Pty. Limited Australia Imaxeon Pty. Ltd. Australia Monsanto Australia Pty Ltd Bangladesh Bayer CropScience Ltd. Belgium Bayer Agriculture BVBA Belgium Bayer CropScience NV Belgium Bayer NV Bermuda MonSure Limited Bolivia Bayer Boliviana Ltda Bolivia Monsanto Bolivia S.A. Bosnia & Herzeg. Bayer d.o.o. Sarajevo Brazil Alkagro do Brasil Ltda Brazil Bayer S.A. Brazil D&PL Brasil Ltda Brazil Monsanto do Brasil Ltda. Brazil Rede Agro Fidelidade e Intermediacao S.A. Brazil Schering do Brasil Química e Farmacêutica Ltda. Brazil Stoneville Brasil Ltda. Bulgaria Bayer Bulgaria EOOD Burkina Faso Monsanto Burkina Faso SARL Chile Bayer Finance & Portfolio Management S.A. Chile Bayer Finance Ltda. Chile Bayer S.A. Chile Monsanto Chile, S.A. Costa Rica Bayer Business Services Costa Rica, SRL Costa Rica Bayer Medical S.R.L. Costa Rica Bayer S.A. Curacao Pianosa B.V. Germany Adverio Pharma GmbH - 1 - List of active Bayer companies with at least a share of 50% last update: 17.8.2020 Country Company Germany AgrEvo Verwaltungsgesellschaft mbH Germany Alcafleu Management GmbH & Co. KG Germany BGI Deutschland GmbH Germany Bayer 04 Immobilien GmbH Germany Bayer 04 Leverkusen Fußball GmbH Germany Bayer 04 Leverkusen
  • Market Data from Deutsche Börse

    Market Data from Deutsche Börse

    Market Data + Services Market data from Deutsche Börse Real-time. Reliable. Relevant. Deutsche Börse is a global German company Providing access to international capital markets Market data from Deutsche Börse 3 Deutsche Börse Group A global market operator Deutsche Börse Group, whose history dates back to 1585, is today one of the largest exchange organisations world-wide. The Group is headquartered in Germany and has more than 4,000 employees working to provide investors, financial institutions and companies access to global capital markets. Deutsche Börse Group’s integrated business model covers the entire process chain from securities and derivatives trading, clearing, settlement and custody, through to market data and the development and operation of electronic trading systems. Deutsche Börse Group owns the derivatives trading venue Eurex Exchange, as well as the settlement and custody business Clearstream. The Group’s market data business, operated by Market Data + Services, is trusted by more than 2,500 institutions and 160,000 subscribers. Deutsche Börse Group’s business areas Deutsche Börse Group Eurex Xetra Clearstream Market Data + Exchange Services Cash Settlement, market trading financing services Derivatives Information, indices, market trading tools, market solutions Simplified illustration Trademarks AlphaFlash ®, CEF ®, DAX ®, Eurex ® and Xetra ® are registered trademarks of Deutsche Börse AG. STOXX ® and EURO STOXX 50 ® are registered trademarks of STOXX Limited. Information is the basis for successful decision making